(Boursier.com) — Onxeo SA, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms and pilot oncogenes, today announces its financial calendar for fiscal year 2023.
Extraordinary General Meeting: Monday, February 6, 2023
2022 annual results: Thursday, March 30, 2023
Annual General Meeting: Wednesday, May 17, 2023
First-half 2023 results: Thursday, September 28, 2023.
©2023 Boursier.com